Discovery of Novel Disubstituted l-Prolinamide Derivatives as Selective PI3Kα Inhibitors for Anticancer Therapy

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• PIK3CA gene mutations are common drivers in various cancers.
• Targeting PI3Kα (phosphoinositide 3-kinase alpha) with small-molecule inhibitors is a crucial therapeutic strategy for PIK3CA-mutated cancers.
• Several selective PI3Kα inhibitors are currently in clinical development.

Purpose of the Study:

• To design and synthesize novel PI3Kα inhibitors with high selectivity.
• To identify an ideal PI3Kα inhibitor for potential cancer treatment.

Main Methods:

• Comparative analysis of amino acid residues in the ATP-binding pockets of PI3K isoforms (α, β, γ, δ), focusing on hinge regions.
• Design and synthesis of novel disubstituted l-prolinamide derivatives.
• Biological evaluation of synthesized compounds for PI3Kα selectivity and pharmacokinetic properties, including in vivo efficacy studies.

Main Results:

• Compound 26 demonstrated significant selectivity for PI3Kα over PI3Kβ (1268-fold), PI3Kγ (350-fold), and PI3Kδ (206-fold).
• Compound 26 exhibited favorable pharmacokinetic properties.
• In vivo efficacy studies indicated promising preclinical potential for compound 26.

Conclusions:

• Novel disubstituted l-prolinamide derivatives were successfully designed and synthesized.
• Compound 26 represents a highly selective PI3Kα inhibitor with significant preclinical therapeutic potential for PIK3CA-mutated cancers.
• Further investigation into compound 26 is warranted for cancer treatment development.